Cambridge, Mass.– MOMA Therapeutics, a clinical-stage biopharmaceutical company specializing in precision therapeutics, has announced the appointment of Susan Pandya, M.D., as an independent member of its board of directors. The company has also named Neil Lineberry, Ph.D., as head of corporate development, strengthening its leadership as it advances multiple clinical-stage programs.
Dr. Pandya, a seasoned oncologist and industry executive, brings nearly two decades of experience in oncology drug development. Currently serving as vice president of clinical development and global head of late-stage oncology at Servier Pharmaceuticals, she has been instrumental in guiding clinical strategies across multiple hematology and oncology programs. Her previous work at Agios Pharmaceuticals contributed to several FDA approvals in mutant-IDH indications, including advanced or metastatic cholangiocarcinoma and acute myeloid leukemia.
“We are thrilled to welcome Susan during this exciting time as we advance all three of our lead assets toward responses in the clinic,” said Asit Parikh, M.D., Ph.D., chief executive officer of MOMA. “Her extensive expertise in oncology clinical development, coupled with her deep understanding of patient needs, makes her an invaluable addition to our leadership team.”
Dr. Pandya expressed enthusiasm for her new role, stating, “MOMA is in a position to take DNA damage response to the next frontier. I look forward to working with the rest of the board and MOMA’s management team to help advance this portfolio toward demonstrating potentially transformative benefits for patients in the clinic.”
MOMA Therapeutics is actively progressing its clinical pipeline, with MOMA-313, a selective Polθ helicase inhibitor, moving into the combination arm of a Phase 1a dose-escalation study with the approved PARP inhibitor olaparib. The company anticipates entering the clinic with MOMA-341, a novel covalent Werner helicase inhibitor, in Q2 2025, and reaching IND stage for MOMA-989, a next-generation selective PARP1 inhibitor, in Q4 2025.
In addition to Dr. Pandya’s appointment, MOMA has named Neil Lineberry, Ph.D., as head of corporate development. Dr. Lineberry, a life science leader with over 20 years of industry experience, most recently served as a global program lead at Takeda Pharmaceuticals. There, he spearheaded clinical-stage oncology programs, secured worldwide regulatory approvals for Fruzaqla® in metastatic colorectal cancer, and advanced two next-generation immuno-oncology programs into early clinical development. His previous roles include leading R&D integration efforts following Takeda’s acquisition of Shire Pharmaceuticals and contributing to China business unit development strategy.
Dr. Lineberry’s new responsibilities at MOMA will encompass corporate strategy, new product planning, investor relations, and business development. His appointment is expected to play a key role in shaping the company’s growth and strategic direction.
With these strategic additions to its leadership team, MOMA Therapeutics is poised to accelerate its mission of developing next-generation precision medicines aimed at improving patient outcomes in oncology.
